Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Income towards Parent Company: 2014-2025

Historic Income towards Parent Company for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$35.1 million.

  • Viridian Therapeutics, Inc.\DE's Income towards Parent Company rose 54.18% to -$35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 17.75%. This contributed to the annual value of -$269.9 million for FY2024, which is 13.55% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Income towards Parent Company stood at -$35.1 million for Q3 2025, which was up 65.20% from -$100.7 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Income towards Parent Company registered a high of -$14.0 million during Q3 2021, and its lowest value of -$100.7 million during Q2 2025.
  • Moreover, its 3-year median value for Income towards Parent Company was -$66.9 million (2023), whereas its average is -$66.4 million.
  • Within the past 5 years, the most significant YoY rise in Viridian Therapeutics, Inc.\DE's Income towards Parent Company was 68.11% (2021), while the steepest drop was 177.41% (2021).
  • Viridian Therapeutics, Inc.\DE's Income towards Parent Company (Quarterly) stood at -$28.9 million in 2021, then crashed by 58.17% to -$45.8 million in 2022, then tumbled by 46.03% to -$66.9 million in 2023, then declined by 19.33% to -$79.8 million in 2024, then spiked by 54.18% to -$35.1 million in 2025.
  • Its last three reported values are -$35.1 million in Q3 2025, -$100.7 million for Q2 2025, and -$86.9 million during Q1 2025.